NASDAQ:CKPT Checkpoint Therapeutics (CKPT) Stock Price, News & Analysis $2.10 -0.05 (-2.33%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$2.06▼$2.2050-Day Range$2.05▼$2.6852-Week Range$1.30▼$3.62Volume389,360 shsAverage Volume454,569 shsMarket Capitalization$74.94 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Checkpoint Therapeutics alerts: Email Address Checkpoint Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside471.4% Upside$12.00 Price TargetShort InterestBearish11.75% of Float Sold ShortDividend StrengthN/ASustainability-0.63Upright™ Environmental ScoreNews Sentiment0.12Based on 3 Articles This WeekInsider TradingSelling Shares$77,309 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.81) to $0.11 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.11 out of 5 starsMedical Sector348th out of 910 stocksPharmaceutical Preparations Industry150th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingCheckpoint Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCheckpoint Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Checkpoint Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted11.75% of the float of Checkpoint Therapeutics has been sold short.Short Interest Ratio / Days to CoverCheckpoint Therapeutics has a short interest ratio ("days to cover") of 11.3, which indicates bearish sentiment.Change versus previous monthShort interest in Checkpoint Therapeutics has recently increased by 0.71%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCheckpoint Therapeutics does not currently pay a dividend.Dividend GrowthCheckpoint Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCheckpoint Therapeutics has received a 62.36% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Checkpoint Therapeutics is -0.63. Previous Next 1.7 News and Social Media Coverage News SentimentCheckpoint Therapeutics has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Checkpoint Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 7 people have searched for CKPT on MarketBeat in the last 30 days. This is a decrease of -42% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Checkpoint Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Checkpoint Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $77,309.00 in company stock.Percentage Held by InsidersOnly 2.10% of the stock of Checkpoint Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 22.00% of the stock of Checkpoint Therapeutics is held by institutions.Read more about Checkpoint Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Checkpoint Therapeutics are expected to grow in the coming year, from ($0.81) to $0.11 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Checkpoint Therapeutics is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Checkpoint Therapeutics is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Checkpoint Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Sasco Gold LLCSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late... [RUSH MY FREE GUIDE] About Checkpoint Therapeutics Stock (NASDAQ:CKPT)Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.Read More CKPT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CKPT Stock News HeadlinesSeptember 6 at 12:08 AM | yahoo.comCharlotte Airport Checkpoint C closing Thursday for constructionSeptember 4 at 8:00 AM | globenewswire.comCheckpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 7, 2024 | Paradigm Press (Ad)Ex-CIA Advisor: “This is How Kamala will Rig the Election”A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s plan to stop Trump. Every American needs to prepare now…September 4 at 7:39 AM | yahoo.comCLT Airport Checkpoint C closing, new American counters open in next step of expansionAugust 27, 2024 | tmcnet.comCCL Label Debuts Innovative RFID Solutions at Labelexpo 2024 with Checkpoint SystemsAugust 20, 2024 | businesswire.comEMulate Therapeutics Inc. Announces Publication of Pre-Clinical Mouse Model Demonstrating Direct Evidence of Immune Checkpoint Receptor Knock-Down in a Mouse Glioblastoma ModelAugust 20, 2024 | msn.comCheckpoint Therapeutics files secondary offering of up to 5.9M sharesAugust 16, 2024 | msn.comBurbank Police to Conduct DUI Checkpoint on SaturdaySeptember 7, 2024 | Paradigm Press (Ad)Ex-CIA Advisor: “This is How Kamala will Rig the Election”A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s plan to stop Trump. Every American needs to prepare now…August 14, 2024 | finanznachrichten.deFortress Biotech, Inc.: Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate HighlightsAugust 14, 2024 | finance.yahoo.comIndividual investors account for 57% of Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) ownership, while public companies account for 9.8%August 14, 2024 | finanznachrichten.deCheckpoint Therapeutics, Inc: Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate UpdatesAugust 12, 2024 | globenewswire.comCheckpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate UpdatesJuly 25, 2024 | marketwatch.comCheckpoint Therapeutics Shares Rise After FDA Accepts Resubmission of CosibelimabJuly 25, 2024 | markets.businessinsider.comCheckpoint Therapeutics Says FDA Accepted BLA Resubmission Of CosibelimabJuly 25, 2024 | globenewswire.comCheckpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell CarcinomaJuly 15, 2024 | globenewswire.comGC Cell and Checkpoint Therapeutics Advance Collaborative Cancer ResearchJuly 2, 2024 | globenewswire.comCheckpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesSee More Headlines Receive CKPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Checkpoint Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/12/2024Today9/07/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CKPT CUSIPN/A CIK1651407 Webwww.checkpointtx.com Phone(781) 652-4500FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$20.00 Low Stock Price Target$4.00 Potential Upside/Downside+471.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51,850,000.00 Net Margins-50,336.89% Pretax Margin-54,444.87% Return on EquityN/A Return on Assets-672.98% Debt Debt-to-Equity RatioN/A Current Ratio0.26 Quick Ratio0.26 Sales & Book Value Annual Sales$78,000.00 Price / Sales960.78 Cash FlowN/A Price / Cash FlowN/A Book Value($0.35) per share Price / Book-6.00Miscellaneous Outstanding Shares35,686,000Free Float34,937,000Market Cap$74.94 million OptionableOptionable Beta1.25 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesMr. James F. Oliviero III (Age 48)C.F.A., President, CEO & Director Comp: $921.59kMr. William Garrett Gray (Age 37)CFO, Corporate Secretary & Treasurer Comp: $409.12kKey CompetitorsLeap TherapeuticsNASDAQ:LPTXAC ImmuneNASDAQ:ACIUEditas MedicineNASDAQ:EDITAurora CannabisNASDAQ:ACBTScan TherapeuticsNASDAQ:TCRXView All CompetitorsInsiders & InstitutionsPVG Asset Management CorpBought 137,194 shares on 8/22/2024Ownership: 0.384%B. Riley Wealth Advisors Inc.Bought 180,050 shares on 8/19/2024Ownership: 0.642%Armistice Capital LLCSold 210,000 shares on 8/15/2024Ownership: 7.022%XTX Topco LtdBought 15,605 shares on 8/12/2024Ownership: 0.044%Renaissance Technologies LLCSold 194,017 shares on 8/9/2024Ownership: 0.216%View All Insider TransactionsView All Institutional Transactions CKPT Stock Analysis - Frequently Asked Questions How have CKPT shares performed this year? Checkpoint Therapeutics' stock was trading at $2.29 on January 1st, 2024. Since then, CKPT stock has decreased by 8.3% and is now trading at $2.10. View the best growth stocks for 2024 here. How were Checkpoint Therapeutics' earnings last quarter? Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) released its quarterly earnings results on Monday, August, 12th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.11. The firm had revenue of $0.04 million for the quarter. When did Checkpoint Therapeutics' stock split? Shares of Checkpoint Therapeutics reverse split on Sunday, December 4th 2022. The 1-10 reverse split was announced on Sunday, December 4th 2022. The number of shares owned by shareholders was adjusted after the market closes on Sunday, December 4th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Checkpoint Therapeutics' major shareholders? Top institutional investors of Checkpoint Therapeutics include Armistice Capital LLC (7.02%), B. Riley Wealth Advisors Inc. (0.64%), PVG Asset Management Corp (0.38%) and Renaissance Technologies LLC (0.22%). Insiders that own company stock include James F Oliviero III and William Garrett Gray. View institutional ownership trends. How do I buy shares of Checkpoint Therapeutics? Shares of CKPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Checkpoint Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Checkpoint Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), PTC Therapeutics (PTCT), Dynavax Technologies (DVAX), VBI Vaccines (VBIV) and SCYNEXIS (SCYX). This page (NASDAQ:CKPT) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Checkpoint Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Checkpoint Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CKPT Stock Alerts